Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Timothy LaBranche"'
Autor:
Xiaofang Wang, Li Jiang, Ka Thao, Caroline R. Sussman, Timothy LaBranche, Michael Palmer, Peter C. Harris, G. Stanley McKnight, Klaus P. Hoeflich, Stefanie Schalm, Vicente E. Torres
Publikováno v:
J Am Soc Nephrol
BACKGROUND: Upregulation of cAMP-dependent and cAMP-independent PKA signaling is thought to promote cystogenesis in polycystic kidney disease (PKD). PKA-I regulatory subunit RIα is increased in kidneys of orthologous mouse models. Kidney-specific kn
Autor:
Tina Zimmermann, Steven Bench, Andrea Romagnani, Klaus P. Hoeflich, Carsten Wolter, Michael Sheets, Kerrie Faia, Kerry-Ann Bright, Timothy LaBranche, Marion Dorsch, Alberto Toso, Gordon Heidkamp, James R. Bischoff, Alison Ribeiro, Joshua Close, Marina Bacac, Felix Scheuplein, Nisha Perez, Caitlin Utt, Emanuele Perola, Jan Eckmann, Kristina Fetalvero, Stefan Gross, Qiongfang Cao, Debora Paduraru, Grace O. Silva, Chaoyang Ye, Marly I. Roche, Luke Green, Erin O’Hearn, Tary Traore, Weifan Weng, Jason D. Brubaker, Joseph Kim, Michael Burke, Sylvia Herter, Chandra Miduturu, Erik Gerson, Tim Guzi, Rich Woessner
Publikováno v:
Cancer Research. 81:1717-1717
Hematopoietic progenitor kinase 1 (HPK1, MAP4K1) is a serine/threonine kinase that has been demonstrated to have suppressive effects across a range of immune cells, including T cells and dendritic cells. Loss of MAP4K1 kinase activity is sufficient t
Autor:
Darshan S. Sappal, Vivek Kadambi, Riadh Lobbardi, Joseph L. Kim, Adam Shutes, Michael Palmer, Nicolas Stransky, Robert M. Campbell, Richard Woessner, Timothy LaBranche, Klaus P. Hoeflich, Neil Bifulco, Andrew P. Garner, Grace O. Silva, Erin O’Hearn, Kevin J. Wilson, Timothy J. Guzi, Stefanie Schalm, Marion Dorsch, Lucian DiPietro, Stephen D. Miller, Christoph Lengauer
Publikováno v:
Molecular Cancer Therapeutics. 18:B127-B127
Introduction: Fibrolamellar Carcinoma (FLC) is a rare primary liver malignancy, affecting children and young adults without chronic liver disease. FLC tumors are largely resistant to chemotherapy, making the identification of effective treatment opti
Autor:
Joseph L. Kim, Oleg Schmidt-Kittler, Yemarshet K. Gebreyohannes, Timothy Guzi, Kevin J. Wilson, Alison J. Davis, Alexandra K. Gardino, Adam Shutes, Christoph Lengauer, Lucian DiPietro, Stephen D. Miller, Brian L. Hodous, Yulian Zhang, Doug Wilson, Timothy LaBranche, Nicholas Lydon, Michael Heinrich, Nancy Kohl, Patrick Schöffski, Natasja Brooijmans, Agnieszka Wozniak, Erica Evans, Xing Julia Zhu, Daniel J. DeAngelo, Andy Boral, Beni B. Wolf
Publikováno v:
Science Translational Medicine. 9
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Autor:
Timothy J. Guzi, Jason D. Brubaker, Beni B. Wolf, Christoph Lengauer, Douglas Wilson, Timothy LaBranche, Michelle Maynard, Lucian Dipietro, Joseph L. Kim, Wei Hu, Kevin J. Wilson, Michael Sheets, Erica Evans, Qiangfang Cao, Rami Rahal
Publikováno v:
Clinical Cancer Research. 24:B01-B01
Activating RET fusions have been observed in 1-2% of non-small cell lung adenocarcinomas (NSCLC). These tumors often occur in non-smokers and lack other driver mutations, similar to NSCLC driven by activation of the tyrosine kinases EGFR, ALK or ROS.
Autor:
Joseph L. Kim, Douglas Wilson, Qiongfang Cao, Erica Evans, Paul E. Fleming, Timothy J. Guzi, Timothy LaBranche, Wei Hu, Kevin J. Wilson, Michael Sheets, Beni B. Wolf, Rami Rahal, Lucian Dipietro, Jason D. Brubaker, Michelle Maynard, Christoph Lengauer
Publikováno v:
Molecular Cancer Therapeutics. 17:B151-B151
Introduction: CCDC6-RET/PTC1 (papillary thyroid cancer gene 1) was one of the first gene fusions identified from a malignant epithelial tumor. Over the past 5 years, additional cancer types have been found to have oncogenic RET fusions, most notably